BRKR Stock Analysis: Bruker | NASDAQ

Spectroscopy, Microscopy, X-ray, Superconductors

Total Rating 44

Safety 81

Buy Signal -1.35

Medical Devices
Industry Rotation: +0.8

Market Cap: 9.45B
Avg Turnover: 122M

Risk 3d forecast

Volatility66.6%

VaR 5^th Pctl10.5%

VaR vs Median-3.84%

Reward TTM

Sharpe Ratio0.90

Rel. Str. IBD85.3

Rel. Str. Peer Group18.3 pctl

Character TTM

Beta1.137

Beta Downside1.470

Hurst Exponent0.469

Choppyness80.7%

Drawdowns 3y

Max DD68.72%

CAGR/Max DD-0.01

CAGR/Mean DD-0.02

EPS (Earnings per Share)

EPS CAGR: -14.61%
EPS Trend: -93.9%

Last SUE: 1.52
Qual. Beats: 2

Revenue

Rev. CAGR: 7.86%
Rev. Trend: 92.1%

Last SUE: -1.12
Qual. Beats: -1

Warnings

High Debt/EBITDA With Thin Interest Coverage

Interest Coverage Ratio Critical

Fakeout

Choppy

Tailwinds

Seasonal Tailwind

Seasonality 11.7 years of data

Jan -0.5% 20

Feb -1.5% 8

Mar -2.1% 27

Apr -1.6% 32

May +0.6% 5

Jun +2.5% 22

Jul +5.3% 22

Aug -6.1% 34

Sep -2.7% 6

Oct -2.0% 14

Nov +8.8% 58

Dec -0.6% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: BRKR Bruker

Bruker Corporation (NASDAQ: BRKR) is a U.S.-based manufacturer of scientific instruments and analytical/diagnostic solutions, headquartered in Billerica, Massachusetts, and founded in 1960. The company operates through four reporting segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST).

Its product portfolio spans magnetic resonance spectroscopy (NMR and EPR), preclinical imaging, mass spectrometry, molecular diagnostics kits, PCR technologies, X-ray and fluorescence instrumentation, atomic force microscopy, and laboratory automation/digitalization tools. Through its BEST segment, Bruker also supplies metallic low-temperature superconductors and related wire products used in research and large-scale physics applications such as synchrotron and beamline instrumentation.

As a member of the Life Sciences Tools & Services sub-industry, Bruker sells primarily to pharmaceutical, biotechnology, academic, government, and industrial research customers on a business-to-business basis. Its revenue model combines capital equipment sales with recurring aftermarket service, consumables, and lifecycle support contracts, which is typical for high-end scientific instrument vendors.

Headlines to Watch Out For

BioSpin proteomics sales accelerate on biopharma demand
China tariffs and academic funding cuts pressure Nano segment margins
Acquisition integration costs compress operating margins

Piotroski VR-10 (Strict) 3.0

Net Income: -71.2m TTM > 0 and > 6% of Revenue
FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.77 > 1.0
NWC/Revenue: 29.15% < 20% (prev 23.68%; Δ 5.47% < -1%)
CFO/TA 0.03 > 3% & CFO 190.4m > Net Income -71.2m
Net Debt (1.90b) to EBITDA (247.7m): 7.69 < 3
Current Ratio: 1.85 > 1.5 & < 3
Outstanding Shares: last quarter (152.2m) vs 12m ago 0.33% < -2%
Gross Margin: 46.69% > 18% (prev 48.25%; Δ -1.56% > 0.5%)
Asset Turnover: 56.48% > 50% (prev 54.30%; Δ 2.17% > 0%)
Interest Coverage Ratio: 0.29 > 6 (EBIT TTM 17.6m / Interest Expense TTM 61.5m)

Altman Z'' 3.05

A: 0.17 (Total Current Assets 2.23b - Total Current Liabilities 1.20b) / Total Assets 6.05b
B: 0.38 (Retained Earnings 2.29b / Total Assets 6.05b)
C: 0.00 (EBIT TTM 17.6m / Avg Total Assets 6.20b)
D: 0.66 (Book Value of Equity 2.40b / Total Liabilities 3.63b)
Altman-Z'' = 3.05 = A

Beneish M -2.88

DSRI: 1.17 (Receivables 875.4m/738.7m, Revenue 3.50b/3.44b)
GMI: 1.03 (GM 48.25% / 46.69%)
AQI: 0.95 (AQ_t 0.51 / AQ_t-1 0.54)
SGI: 1.02 (Revenue 3.50b / 3.44b)
TATA: -0.04 (NI -71.2m - CFO 190.4m) / TA 6.05b)
Beneish M = -2.88 (Cap -4..+1) = A

What is the price of BRKR shares?

As of November 04, 2026, the stock is trading at USD 56.50 with a total of 4,339,422 shares traded. Over the past week, the price has changed by -6.98%, over one month by -11.53%, over three months by -12.07% and over the past year by +46.58%.

Current recommended Stop Loss: 52.40 (which is 7.3% or 1.4 ATR below the current price).

Is BRKR a buy, sell or hold?

Bruker has received a consensus analysts rating of 3.69. Therefore, it is recommended to hold BRKR.

StrongBuy: 5
Buy: 1
Hold: 6
Sell: 0
StrongSell: 1

What are the forecasts/targets for the BRKR price?

Analysts Target Price	63.8	13%

Bruker (BRKR) - Fundamental Data Overview as of 31 October 2026

Market Cap USD = 9.45b (9.45b USD * 1.0 USD.USD)
P/E Forward = 13.8313
P/S = 2.6992
P/B = 3.8861
P/EG = 1.5155
Revenue TTM = 3.50b USD
EBIT TTM = 17.6m USD
EBITDA TTM = 247.7m USD
Long Term Debt = 1.81b USD (from longTermDebt, last quarter)
Short Term Debt = 101.0m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 173.8m
Net Debt = 1.90b USD (calculated: Debt 2.09b - CCE 184.9m)
Enterprise Value = 11.4b USD (9.45b + Debt 2.09b - CCE 184.9m)
Interest Coverage Ratio = 0.29 (Ebit TTM 17.6m / Interest Expense TTM 61.5m)
EV/FCF = 120.9x (Enterprise Value 11.4b / FCF TTM 93.9m)
FCF Yield = 0.83% (FCF TTM 93.9m / Enterprise Value 11.4b)
FCF Margin = 2.68% (FCF TTM 93.9m / Revenue TTM 3.50b)
Net Margin = -2.03% (Net Income TTM -71.2m / Revenue TTM 3.50b)
Gross Margin = 46.69% ((Revenue TTM 3.50b - Cost of Revenue TTM 1.87b) / Revenue TTM)
Gross Margin QoQ = 49.61% (prev 47.28%)
Tobins Q-Ratio = 1.88 (Enterprise Value 11.4b / Total Assets 6.05b)
Interest Expense / Debt = 2.94% (Interest Expense 61.5m / Debt 2.09b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 13.9m (EBIT 17.6m * (1 - 21.00%))
Current Ratio = 1.85 (Total Current Assets 2.23b / Total Current Liabilities 1.20b)
Debt / Equity = 0.87 (Debt 2.09b / totalStockholderEquity, last quarter 2.40b)
Debt / EBITDA = 7.69 (Net Debt 1.90b / EBITDA 247.7m)
Debt / FCF = 20.28 (Net Debt 1.90b / FCF TTM 93.9m)
Total Stockholder Equity = 2.43b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.15% (Net Income -71.2m / Total Assets 6.05b)
RoE = -2.92% (Net Income TTM -71.2m / Total Stockholder Equity 2.43b)
RoCE = 0.41% (EBIT 17.6m / Capital Employed (Equity 2.43b + L.T.Debt 1.81b))
RoIC = 0.29% (NOPAT 13.9m / Invested Capital 4.77b)
WACC = 8.17% (E(9.45b)/V(11.5b) * Re(9.46%) + D(2.09b)/V(11.5b) * Rd(2.94%) * (1-Tc(0.21)))
Discount Rate = 9.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.52 | Cagr: 1.90%
[DCF] Terminal Value 77.97% ; FCFF base≈76.1m ; Y1≈87.2m ; Y5≈128.3m
[DCF] Fair Price = 0.17 (EV 1.93b - Net Debt 1.90b = Equity 26.4m / Shares 152.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -93.85 | EPS CAGR: -14.61% | SUE: 1.52 | # QB: 2
Revenue Correlation: 92.10 | Revenue CAGR: 7.86% | SUE: -1.12 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.42 | Chg30d=-0.91% | Revisions=+0% | Analysts=12
EPS current Year (2026-12-31): EPS=2.12 | Chg30d=-0.11% | Revisions=-40% | GrowthEPS=+15.8% | GrowthRev=+3.5%
EPS next Year (2027-12-31): EPS=2.40 | Chg30d=+0.54% | Revisions=+50% | GrowthEPS=+13.4% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: +10% (up=4, down=3)